Skip to content

Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.

Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh, Nastaran Talaee, Eghbal Jasemi, Ali Razmi, Salar Vaseghi

Behavioral Neuroscience January 18, 2024 DOI: 10.1037/bne0000579 via OpenAlex

Summary

AI-generated from the abstract

A single injection of Psilocybe cubensis extract (25 mg/kg) given to male rats shortly before or after fear conditioning reduced PTSD-like freezing behavior in the short term (1 and 3 days after conditioning) but not after 21 days. The extract also decreased locomotor activity only briefly after administration, while it raised pain thresholds and reduced anxiety for a longer period. These results suggest that the mushroom's effects on PTSD-like behavior and activity are short-lived, but its influence on pain sensitivity and anxiety may persist.

Study at a glance

Characteristics Preclinical study Peer reviewed
Population Male rats
Intervention Psilocybe cubensis extract
Dose 25 mg/kg
Topics Anxiety Psilocybin
Keywords Psychology
Citations 22
Key finding Psilocybe cubensis extract alleviated PTSD-like freezing behavior in rats in the short term but not long term, while its effects on pain threshold and anxiety persisted.

Abstract

Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on posttraumatic stress disorder (PTSD)-like behavior, pain perception, locomotor activity, and anxiety in a rat model of PTSD. Male rats were exposed to three consecutive shocks (0.8 mA, 3 s interval) paired with three sounds broadcasted 3 s before delivering shocks (75 dB, 3 s). After 1, 3, or 21 days, freezing rate was measured in the fear-conditioning apparatus. Open filed test and hot plate were used to assess locomotor activity and anxiety, and pain subthreshold, respectively. Psilocybe cubensis was injected intraperitoneal at the dose of 25 mg/kg (single administration) before (pretrain) or after (posttrain) shocks, or before the test (pretest). Results showed psilocybin potently alleviated PTSD symptom is short- but not long-term after the induction of PTSD. Psilocybe cubensis decreased locomotor activity only in a short period after administration. Psilocybe cubensis also increased pain subthreshold and decreased anxiety. In conclusion, Psilocybe cubensis effects on PTSD-like behavior and locomotor activity seem to be remained in short-term, while Psilocybe cubensis effects on pain subthreshold and anxiety remained long-term. This is the first study evaluating the effect of Psilocybe cubensis on PTSD-like behavior in rats in three different time protocols (1, 3, and 21 days after fear conditioning). (PsycInfo Database Record (c) 2024 APA, all rights reserved).

Explore topics

Comments

No comments yet.

Log in to comment